Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial
He has testified before the Senate Working Group on Health Care Reform on Functional Medicine, and participated in the White House Forum on Prevention and Wellness
We have decades of evidence showing that chronic manipulation of enteric signaling (i.e., telling different sections of the digestive tract what to do and when), whether through opioids, supplements, or antidepressants, produces adaptations that outlast the drug itself
Thats where targeted supplementation comes in
Autophagosome supports coxsackievirus B3 replication in host cells
USB-C is definitely the future and I'm so excited about it